It was concluded that neither vitamin E nor metformin treatments had significant differences in ALT reduction, NAFLD activity score, and other histological evidence (including hepatocellular ballooning, fibrosis, steatosis, and lobular inflammation) [59]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.